Christopher Horvath

Dr. Horvath is currently Senior Vice President of PreClinical Development at bluebird bio, a gene therapy company developing products for diseases related to genetic deficiencies. He is currently responsible for pharmacology, bioassay development (nonclinical and clinical), PK, PD, toxicology and pathology. Christopher has worked on numerous products intended to modify complement pathways and complement-mediated diseases, and on several other products whose toxicity profiles included activation of complement pathways.